|By PR Newswire||
|March 18, 2014 07:00 AM EDT||
CHATHAM, N.J. and JAMISON, Pa., March 18, 2014 /PRNewswire/ -- Quinnova Pharmaceuticals LLC, an affiliate of Exeltis™, today announced the launch of its recently U.S. Food and Drug Administration approved ECOZA™ (econazole nitrate) topical foam, 1%. ECOZA™ FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.
ECOZA™ FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology®. Proven to kill fungi that cause interdigital tinea pedis when applied once-daily for 4 weeks, its unique, alcohol-free foam delivery helps protect and restore skin, penetrating quickly and drying rapidly without the greasy residue that is common among other creams and gels.
"We are really excited about the launch of ECOZA™ FOAM, the first and only FDA approved prescription econazole nitrate foam in the U.S., into the almost $600M global athletes foot market. Econazole nitrate is a safe and effective topical antifungal, having been one of the most widely prescribed for the past two decades. This dosage form, using our patented Proderm Technology® that consists of a unique chemical structure that facilitates penetration of drug ingredients into the dermal layer, addresses an unmet consumer need because it is easy to apply, quickly disperses, and does not leave a residue," said Jeffrey S. Day, Executive Vice President, Dermatology of Quinnova Pharmaceuticals. "We are pleased that ECOZA™ FOAM is now available to offer doctors and their patients a safe and effective alternative to traditional creams and gels."
Information About ECOZA™ (econazole nitrate) topical foam, 1%.
ECOZA™ FOAM is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. ECOZA™ FOAM should be applied to cover affected areas once daily for 4 weeks. ECOZA™ FOAM is for topical use only and is not for oral, ophthalmic, or intravaginal use.
In two double-blind, parallel-group, vehicle-controlled, multicenter clinical trials, 495 subjects aged ≥12 years with a clinical diagnosis of interdigital tinea pedis and fungal culture positive for a dermatophyte at baseline received ECOZA™ FOAM (n=246) or foam vehicle (n=249). Subjects applied ECOZA™ FOAM or foam vehicle once-daily for 4 weeks. The primary endpoint was proportion of subjects who achieved a complete cure (negative KOH, negative fungal culture, no evidence of clinical disease as indicated by complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43). Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent).
The results from the clinical studies demonstrated that ECOZA™ FOAM exhibited superiority over foam vehicle for the primary and secondary endpoints and demonstrated potent antifungal activity against all of the pathogens evaluated with a high mycologic cure rate. The complete cure rate at Day 43 (2 weeks post-treatment) was higher in the ECOZA™ FOAM group (24.3%) than in the foam vehicle group (3.6%). In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% vs the foam vehicle. ECOZA™ FOAM was safe and well tolerated with a safety profile comparable with the foam vehicle. During clinical trials with ECOZA™ FOAM the most common adverse reactions were application site reactions, which occurred in less than 1% of subjects in both the ECOZA™ FOAM and vehicle arms. Click for full prescribing information.
About Quinnova Pharmaceuticals
Quinnova Pharmaceuticals, LLC, is a specialty pharmaceutical company that is an affiliate of the global pharmaceutical company, Exeltis™, and was founded on innovative, patent-protected dermal delivery technologies, which are utilized to transport safe and effective pharmaceutical ingredients, through the epidermis, in unique, convenient, and cosmetically elegant formulations. Addressing a wide variety of skin conditions, Quinnova's mission is to provide superior treatment solutions and product value to clinicians and patients. For more information, visit www.quinnova.com and www.exeltis.com
SOURCE Quinnova Pharmaceuticals, LLC
Dec. 5, 2016 07:30 AM EST Reads: 958
Dec. 5, 2016 07:30 AM EST Reads: 7,030
Dec. 5, 2016 07:15 AM EST Reads: 1,250
Dec. 5, 2016 06:45 AM EST Reads: 1,790
Dec. 5, 2016 06:45 AM EST Reads: 1,591
Dec. 5, 2016 06:45 AM EST Reads: 973
Dec. 5, 2016 06:30 AM EST Reads: 692
Dec. 5, 2016 06:15 AM EST Reads: 859
Dec. 5, 2016 06:00 AM EST Reads: 1,678
Dec. 5, 2016 04:30 AM EST Reads: 5,214
Dec. 5, 2016 04:15 AM EST Reads: 1,614
Dec. 5, 2016 04:00 AM EST Reads: 4,701
Dec. 5, 2016 04:00 AM EST Reads: 5,406
Dec. 5, 2016 04:00 AM EST Reads: 5,115
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 5, 2016 03:30 AM EST Reads: 651